A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
Condition: COVID-19
MeSH terms: COVID-19
Intervention: RBT-9 (90 mg); 0.9% sodium chloride (normal saline)
Intervention description: Subjects will receive a single dose and study duration will be approximately 60 days per subject.; Subjects will receive a single dose and study duration will be approximately 60 days per subject.
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: 2:1 randomization to receive RBT-9:Placebo
Masking: None (Open Label)
Enrollment: 42.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The overall objective is to evaluate the efficacy, tolerability, and safety of a single dose
      of RBT-9 versus placebo in coronavirus disease 2019 (COVID-19) infection in non-critically
      ill adults who are at high risk of progression.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Male or female, ≥18 years of age at Screening.

          2. Confirmed infection with SARS-CoV-2.

          3. High risk of COVID-19 disease progression, defined as:

               1. 18-69 years of age with lymphopenia AND 1 additional risk factor (described
                  below)

               2. 18-69 years of age without lymphopenia AND 2 risk factors (described below)

               3. ≥70 years of age with lymphopenia OR 1 other risk factor (described below)

             Risk Factors:

               -  Documented history of coronary artery disease

               -  Heart failure (New York Heart Association Class 3 or 4)

               -  Chronic lung disease (eg, asthma or chronic obstructive pulmonary disease)
                  requiring treatment

               -  Documented history of stroke

               -  Diabetes mellitus, requiring at least 1 prescription medicine for management

               -  Documented chronic kidney disease with an estimated glomerular filtration rate
                  <30 mL/min, not on dialysis

               -  Obesity (Class 2 or 3; body mass index >34.9 kg/m2)

               -  On immunosuppressive therapy

               -  Oxygen saturation between 90 and 95% with or without supplemental oxygen

          4. Admitted to a hospital for observation and/or treatment (controlled facility may
             include an emergency room, urgent care facility, temporary/modular hospital, infusion
             center, clinical research unit, etc).

          5. If female, must be postmenopausal, surgically sterile, or if of childbearing
             potential, must be practicing 2 effective methods of birth control during the study
             and through 30 days after completion of the study.

          6. For females of childbearing potential, a urine pregnancy test must be negative at the
             Screening Visit.

          7. If male, must be surgically sterile or willing to practice 2 effective methods of
             birth control during the study and through 30 days after completion of the study.

          8. Must be willing and able to give informed consent and comply with all study
             procedures.

        Exclusion Criteria:

          1. Anticipated need for ICU care and/or ventilatory support (invasive or noninvasive)
             within 24 hours.

          2. Evidence of acute cardiac injury, as determined by the Investigator at the time of
             Screening. This may be based upon clinical signs and symptoms, ECG findings, or
             elevated troponin I levels.

          3. Evidence of acute kidney injury not due to pre-renal azotemia or urinary tract
             obstruction at the time of Screening.

          4. Oxygen saturation <90% on supplemental oxygen with a nasal cannula, including
             high-flow oxygen at the time of Screening.

          5. Requires non-invasive ventilation at the time of Screening.

          6. Requires dialysis at the time of Screening.

          7. Has received or is receiving anti-IL-6 therapies (eg, Tocilizumab, Sarilumab,
             Siltuximab, etc) for the treatment of COVID-19; subjects receiving anti-IL-6 therapies
             for underlying medical conditions unrelated to COVID-19 are not excluded from
             eligibility.

          8. Pregnant or lactating.

          9. History of photosensitivity or active skin disease that, in the opinion of the
             Investigator, could be worsened by RBT-9.

         10. Known hypersensitivity or previous anaphylaxis to RBT-9 (stannous protoporphyrin) or
             any tin-based product.

         11. Treatment with an investigational drug or participation in an interventional trial
             within 30 days prior to the first dose of study drug.

         12. Inability to comply with the requirements of the study protocol.